In Burkitt lymphoma cells, CD49d mediated cell adhesion-dependent drug resistance via NF-κB activation; this resistance can be overcome by treatment with the proteasome inhibitor bortezomib, which suppresses NF-κB activation [47]. Here, NFKB1 is linked to Burkitt lymphoma.